Biotech - International Biopharmaceutical Industry

news

Pfizer stocks cancer drug pipeline with $2.3B deal for Trillium

Pfizer is building up its pipeline of experimental cancer medicines, announcing Monday a deal to buy the Cambridge, Massachusetts-based biotech Trillium Therapeutics ...

27 August 2021 news Biotech | cancer drug

Continue Reading →

news

Vertex, looking to broaden its gene editing abilities, asks a young biotech for help

Vertex is best known for its work in cystic fibrosis, having developed four approved medicines that, by the company's estimates, can treat about 90% of the patient po...

27 August 2021 news Biotech | cystic fibrosis

Continue Reading →

news

Merck wins approval for cancer drug acquired in 2019 biotech buyout

Peloton was one of a handful of cancer-focused biotech companies acquired since 2018 by Merck, which has sought to complement its top-selling immunotherapy Keytruda w...

20 August 2021 news ArQule | Biotech

Continue Reading →

news

Private equity dives deeper into biotech with nearly $2B Bain fundraise

The last several years have seen private equity grow more entrenched in healthcare. Using data from Pitchbook, Healthcare Dive found private equity deals in the space...

20 August 2021 news Biotech | Cerevel Therapeutics

Continue Reading →

news

Startup EQRx to take drug price mission public through $1.8B SPAC deal

EQRx, a startup with lofty ambitions to develop competitors to top-selling drugs at much reduced prices, will go public through a merger with a blank-check company ba...

13 August 2021 news Biotech | Casdin Capita

Continue Reading →

news

How Bayer lured a biotech away from an IPO and into a buyout

In what has become a common move by large pharmaceutical companies attempting to revitalize their drug research, German healthcare conglomerate Bayer has acquired a s...

13 August 2021 news Bayer | Biotech

Continue Reading →

news

Gilead’s Kite bets on early-stage biotech to advance allogeneic cell therapies

The deal with Appia is yet another step in Gilead’s efforts to become an oncology powerhouse — a strategy the company has made clear through numerous acquisitions and...

13 August 2021 news allogeneic cell therapies | Biotech

Continue Reading →

news

FDA rejects a biotech’s kidney drug, but some analysts still see a ‘sliver of hope’

The FDA's decision wasn't surprising to analysts, as "deficiencies" in an approval application have become somewhat of a prelude to rejection. This year alone saw two...

5 August 2021 news Acadia Pharmaceuticals | Ardelyx

Continue Reading →

news

Sarepta adds another gene therapy to its ever-expanding pipeline

Sarepta can claim one of the larger pipelines in biotech, with 42 different programs listed by the developer. Twenty-six of those are gene replacement therapies for a...

5 August 2021 news AveXis | Biotech

Continue Reading →

news

Western Australia to get new biotech hub

MTPConnect will match the funding by contributing $100,000 in cash per annum and $200,000 per annum in in-kind support over four years, for joint co-funded activitie...

6 July 2018 news australia | Biotech

Continue Reading →